J&J's COVID-19 Vaccine May Face Efficacy Comparison Questions At US FDA Panel Review

 
• By Sue Sutter

Efficacy against moderate to severe/critical COVID-19 was 66%-67%, well above the FDA’s stated 50% efficacy threshold for an EUA but far short of the 94%+ efficacy rates posted by the Pfizer and Moderna vaccines against symptomatic disease; agency says efficacy against specific variants cannot be evaluated at this time because sequencing data are incomplete.

Rock comparison
It might be difficult for an FDA advisory committee to refrain from comparing and contrasting Janssen's vaccine with two others. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers